SiBone $SIBN Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC lifted its holdings in SiBone (NASDAQ:SIBN) by 13.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 428,061 shares of the company’s stock after purchasing an additional 49,270 shares during the quarter. Peregrine Capital Management LLC’s holdings in SiBone were worth $5,406,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Royal Bank of Canada raised its stake in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares in the last quarter. Assenagon Asset Management S.A. grew its position in SiBone by 0.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock valued at $4,437,000 after buying an additional 997 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after buying an additional 1,053 shares during the period. Larson Financial Group LLC increased its stake in SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after buying an additional 1,061 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after buying an additional 1,459 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at SiBone

In related news, Director Timothy E. Davis, Jr. sold 3,500 shares of SiBone stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $14.14, for a total value of $49,490.00. Following the transaction, the director owned 65,722 shares of the company’s stock, valued at approximately $929,309.08. This trade represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Dunn sold 3,575 shares of SiBone stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the completion of the transaction, the director directly owned 16,057 shares in the company, valued at $244,869.25. This represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 29,875 shares of company stock valued at $437,666. 4.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, TD Cowen lowered their price target on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.00.

SiBone Price Performance

Shares of NASDAQ SIBN opened at $16.80 on Thursday. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average of $14.57 and a two-hundred day moving average of $15.52. The company has a market capitalization of $745.08 million, a price-to-earnings ratio of -43.08 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The company had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. As a group, analysts expect that SiBone will post -0.44 earnings per share for the current fiscal year.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.